Multiple sclerosis (MS) is a degenerative autoimmune disease of the central nervous system (CNS). Autoreactive lymphocytes that infiltrate the CNS attack the myelin sheath of neurons, causing relapses and progressive disability. Evidence from genetic association studies in human subjects and from animal models, such as experimental autoimmune encephalomyelitis (EAE), indicate that CD4
1 T cells play a key pathogenic role. 1, 2 In mice with EAE, different subsets of CD4 1 T cells can mediate disease, including IFN-g-producing T-box transcription factor (T-bet) 1 T H 1 cells and IL-17-producing retinoic acid receptorrelated orphan receptor gt (RORgt) 1 T H 17 cells. 3, 4 T H 1/ T H 17 cells that coexpress RORgt and T-bet and coproduce IFNg and IL-17 are particularly pathogenic, can be generated with IL-23, [5] [6] [7] [8] [9] and are present in lesions of patients with MS. 10 Moreover, GM-CSF is required to induce EAE, 5 and GM-CSF-producing T cells are present in the cerebrospinal fluid (CSF) of patients with MS. 11 However, both T H 1 and T H 17 cells can produce GM-CSF. 3, 9, 11 Moreover, myelin-reactive T cells are present at comparably low frequencies in healthy subjects and patients with MS, 12 although myelin basic protein (MBP)-specific T cells in patients with MS produce increased amounts of proinflammatory cytokine. 13 However, the phenotype of pathogenic precursor T cells in the peripheral blood of patients with MS remains to be defined.
MS can be subdivided into relapsing-remitting (RR) and progressive forms.
14 Therapies with fingolimod and natalizumab interfere with lymphocyte migration and efficiently prevent relapses in patients with RR-MS but have severe side effects. Fingolimod (FTY20) inhibits sphingosine-1-phosphate-mediated egress of T cells from lymph nodes and thus depletes naive and central memory T (T CM ) cells from the circulation. 16 T CM cells are immature memory T cells, express CCR7 and CD62 ligand, home to lymph nodes, and produce IL-21 9 but only limited amounts of other potentially pathogenic effector cytokines. 17, 18 Conversely, effector memory T (T EM ) cells express the inflammatory chemokine receptor CCR5, home to nonlymphoid tissues, and produce high levels of effector cytokines. 17 Natalizumab is a therapeutic antibody that blocks the a4-integrin and, consequently, CNS homing of lymphocytes. 15, 19 Natalizumab is very efficient at preventing relapses but frequently induces reactivation of John Cunningham virus (JCV), 20, 21 which is normally controlled by CD4
1 T cells 22, 23 and can lead to fatal progressive multifocal leukoencephalopathy (PML). 21, 24 PML in immune-compromised subjects and the discovery of a lymphatic system in the CNS have challenged the view of the brain as an immune-privileged site 25 and suggest that persistent neurotropic viruses are continuously controlled by CNS-homing T cells. 24, 26 Notably, the risk of MS is associated with various neurotropic viruses 27, 28 and in particular with EBV. 29 Molecular mimicry was proposed as a possible mechanism because some EBV-specific T cells with a degenerate T-cell receptor (TCR) cross-react with myelin antigens. [30] [31] [32] Nevertheless, a single virus that causes MS was not identified, and the role of viral infections in patients with MS remains enigmatic and debated. [27] [28] [29] We report here that autoreactive T H 1/T H 17 CM cells expand in peripheral blood of patients with RR-MS and accumulate in the CSF on attacks together with virus-specific T H 1 cells, suggesting that these 2 subsets have distinct roles in relapses and immune surveillance.
METHODS

Recruitment, classification, and sample collection for patients with MS
Fifty-five patients with MS were selected at the MS Center of the Fondazione Ca' Granda, IRCCS Ospedale Policlinico, according to the therapy and disease type (RR or progressive). At the time of analysis, no patients with MS were undergoing any treatment unless indicated for fingolimod-and natalizumab-treated patients with RR-MS. The Expanded Disability Status Scale was calculated at the time of diagnosis and over time. The multiple sclerosis severity score (MSSS) was used for measuring the progression of the disability and used to stratify patients with MS with mild disease (MSSS < 1) or more severe disease (MSSS > 1). All patients underwent the standard workup for MS, including medical history, physical and neurological examination, screening laboratory tests, and brain magnetic resonance imaging. Diagnoses met the McDonald criteria. 33 Each patient provided informed consent for participating in the study, and their demographic and clinical data are reported in Table E1 in this article's Online Repository at www.jacionline.org.
PBMCs of 20 healthy donors (HDs) from the Policlinico Blood Bank, 14 patients with RR-MS, 10 patients with progressive MS, 8 natalizumab-treated patients with RR-MS, and 13 fingolimod-treated patients with RR-MS were collected and analyzed. When HDs were compared with patients with MS, a cohort of 20 HDs matched for age and sex to patients with RR-MS (see Table E1 ) were analyzed. All patients with RR-MS who donated blood were in remission. Conversely, CSF samples were obtained from 10 patients with RR-MS shortly after an attack or from 5 nonautoimmune control subjects with dementia. Samples were collected in polypropylene tubes by means of lumbar puncture at the L4/L5 or L3/L4 interspace, centrifuged at 48C and 2000g, and analyzed immediately. Supernatants were removed and stored at 2808C until use. The study was approved by the Institutional Review Board of the Ospedale Policlinico.
Flow cytometry
Eight-color flow cytometric analysis was performed with a FACSCanto II cytometer (Becton Dickinson, Franklin Lakes, NJ) after staining with fluorochrome-conjugated antibodies. Unless indicated, all antibodies were from eBioscience (San Diego, Calif). For surface marker expression, anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD45RA (HI100), anti-CD25 (BC96), anti2IL-7 receptor (IL-7R; eBioRDR5), anti-CXCR3 (1C6), anti-CCR6 (R6H1), anti-CCR5 (2D7), anti-CCR7 (3D12), anti-CD62 ligand (Dreg 56), anti-CD161 (DX12, BD), anti-CD6 (MEM-98; ImmunoTools, Friesoythe, Germany), anti-CD58 (B-A19, ImmunoTools), anti-CD49d (a4-integrin, clone 9F10), anti-CD29 (b1-integrin clone TS2/16) were used. For T-bet intranuclear staining, forkhead box p3 staining buffer set (eBioscience) and anti-T-bet (O4-46, BD Biosciences) were used, according to the manufacturer's recommendations. For intracellular cytokine detection, T cells were incubated for 5 hours in the presence or absence of phorbol 12-myristate 13-acetate (PMA), ionomycin, and brefeldin A (Sigma, St Louis, Mo) in complete RPMI (10% FBS, 1 mmol/L sodium pyruvate, 10 mmol/L nonessential amino acids, and 1% penicillin/streptomycin). Subsequently, cells were surface labeled with conjugated antibodies. After fixation with 2% paraformaldehyde (Merck, Whitehouse Station, NJ), cells were permeabilized with PBS-0.5% saponin (Sigma) and stained with anti-IL-17 (eBio64DEC17), anti-IL-22 (22URTI), anti-IFN-g (4S.B3), anti-GM-CSF (BVD2-21C11), anti-Granzyme A (CB9, BD Biosciences), and anti-CD154 (CD40L, clone [24] [25] [26] [27] [28] [29] [30] [31] antibodies. Fluorescence-activated cell sorting (FACS) data were analyzed with FlowJo software (TreeStar, Ashland, Ore). For intracellular IL-10 detection, T cells were activated in plate-bound anti-CD3 (2 mg/mL, BD Biosciences), as previously described 34 : cells were cultured for 24 hours in the presence of 200 U/mL IL-2, Brefeldin A was added for an additional 6 hours, and cells were analyzed for intracellular IL-10 production after fixation and permeabilization.
IL-23 receptor (IL-23R) expression was determined, as previously described. 9 Briefly, cells were incubated in culture medium with or without 10 ng/mL IL-23 (R&D Systems, Minneapolis, Minn) for 30 minutes and fixed with Cytofix Fixation Buffer (BD Biosciences), followed by permeabilization with Perm Buffer III (BD Biosciences). Thereafter, cells were stained with anti-phospho-signal transducer and activator of transcription (STAT) 3 (pY705; BD Biosciences), and the percentage of phospho-STAT3 1 cells was reported as a percentage of IL-23R responsive cells.
RT-PCR
To measure RORC mRNA levels, we isolated total RNA using the mirVana Kit (Ambion, Thermo Fisher, Waltham, Mass). mRNA expression levels were assessed by using the TaqMan Gene expression assay (Applied Biosystems, Foster City, Calif) and normalized on 18s rRNA.
Cell purification
All FACS sorting was performed with a FACSAria III (BD Biosciences), according to the expression of specific surface markers. For characterization of human helper T-cell subsets from PBMCs and CSF, T cells were stained with the following antibodies in combination: anti-CD4, anti-CD45RA, anti-CD25, anti-IL-7R, anti-CCR6, anti-CXCR3, and anti-CCR5. T H 1 cells were sorted as CD4
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In vitro T-cell differentiation
In vitro differentiation of sorted T H 1 CM and T H 17 cells was performed at 5000 cells/well in plate-bound anti-CD3 (0.02 mg/mL, BD Biosciences) and anti-CD28 antibodies (6 mg/mL, BD Biosciences) in Dulbecco modified Eagle medium (5% human serum, 1 mmol/L sodium pyruvate, 10 mmol/L nonessential amino acids, 1% penicillin/streptomycin, and 25 mmol/L b-mercaptoethanol). 36 Cells were cultured for 4 days under T H 17-promoting conditions (neutralizing antibodies against IL-12 and IL-4 at 2 mg/mL [BD Biosciences] and recombinant human TGF-b1, IL-1b, IL-6, and IL-23) or under T H 1-promoting conditions (neutralizing antibody against IL-4 and recombinant human IL-12). All recombinant cytokines (R&D Systems) were added at 10 ng/ mL, with the exception of TGF-b1, which was used at 1 ng/mL. After 4 days, cells were transferred to uncoated plates and cultured for an additional 7 days under the same cytokine conditions and then analyzed for intracellular cytokine (IL-17 and IFN-g) or CXCR3 and CCR6 surface expression. Because CCR6 upregulation is transient in vitro, 37 it was analyzed on day 4, as previously reported. 9, 36 RNA isolation and gene expression profiling Total RNA was isolated from FACS-purified T-cell subsets from PBMCs by using the mirVana miRNA Isolation Kit (Ambion), according to the standard protocol. Briefly, lysates were extracted once with acid-phenol chloroform and further purified to yield total RNA. Extracted RNA was quantified with the RiboGreen Quantitation Kit (Molecular Probes, Eugene, Ore) on an Infinite F200 plate reader (Tecan Trading AG, M€ annedorf, Switzerland). All extracted RNA samples were quality controlled for integrity with the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, Calif), and samples with RNA integrity numbers of less than 8 were discarded. Gene expression of whole transcriptome was performed on CD4 1 T-cell subsets with Illumina Direct Hybridization Assays (Illumina, San Diego, Calif), according to the standard protocol. For each sample, 80 ng of total RNA was reverse transcribed according to the Illumina TotalPrep RNA Amplification kit (Ambion), and cRNA was generated after 14 hours of in vitro transcription. Washing, staining, and hybridization were performed according to the standard Illumina protocol: briefly, 750 ng of cRNA of each sample in a final volume of 15 mL were hybridized onto Illumina HumanHT-12 v3 Expression BeadChip arrays. Hybridization and scanning were performed according to the manufacturer's indications on an Illumina iScan System, and data were processed with BeadStudio v.3.
Gene expression analysis
Gene expression arrays were quantile normalized with background subtraction, and average signals were calculated on gene-level data for genes with a detection P value of less than .001 in at least 1 of the subsets considered. Normalized data were log 2 transformed and presented as z scores. One-way ANOVA (P < .001) was used to select gene classifiers for all cell subsets profiled. Unsupervised hierarchical clusters on significant genes were performed with Pearson distance and complete linkage. Statistical tests and hierarchical clustering were performed with MeV software, version 4.5 (MultiExperiment Viewer, Boston, Mass).
Autoreactivity and antigen-specificity assays
To assess autoreactivity, T-cell subsets (T H 1 CM , T H 1/T H 17 CM , T H 1/ T H 17 EM , and T H 17) purified from PBMCs of patients with MS or HDs were Cell Trace labeled (Invitrogen, Carlsbad, Calif) and cocultured with autologous CD1c
1 DCs at a 5:1 ratio, as described previously. 34 After 5 days, cells were analyzed by using flow cytometry for Cell Trace dye dilution. Antigenspecific proliferation was determined, as previously described. 18 Briefly, Tcell subsets (T H 1 CM , T H 1/T H 17 CM , and T H 17) isolated from PBMCs of patients with MS or HDs were Cell Trace labeled (Invitrogen) and cocultured with autologous monocytes obtained by using CD14
1 selection (CD14 Microbeads, Miltenyi Biotec) at a 1:1 ratio in the presence or absence of myelin-derived peptides (PepTivatorMOG and MBP Isoform-I; Miltenyi Biotec) or viral peptides (PepTivatorJCV-VP1 or EBV-Consensus; Miltenyi Biotec). All peptides were used at 0.6 nmol/mL. After 7 days, cells were analyzed by means of flow cytometry for Cell Trace dye dilution. Background proliferation induced by autologous monocytes alone was subtracted to calculate antigen-specific proliferation.
Generation and analysis of T-cell lines from CSF of patients with MS
Fresh CSF-derived mononuclear cells were isolated immediately after CSF collection. Two hundred to 10,000 FACS-purified T H 1, T H 1/T H 17, and T H 17 cells were activated in 96-well plates with 10 6 /mL irradiated allogeneic feeder cells, 10 5 /mL irradiated allogeneic EBV-induced lymphoblastoid cell lines, and soluble monoclonal anti-CD3 (0.03 mg/mL, OKT3; BioLegend) in complete RPMI (10% FCS, 1 mmol/L sodium pyruvate, 10 mmol/L nonessential amino acids, and 1% penicillin/streptomycin) supplemented with 200 U/mL human recombinant IL-2 (Miltenyi Biotec). T-cell lines were maintained in the same complete medium and were used in functional assays 15 to 20 days after their last stimulation. In addition, CSF-derived T-cell lines were analyzed for cytokine production, surface marker expression, and TCR-Vb mRNA expression by using PCR, as described previously. 38 T cells were cocultured with autologous CD14
1 monocytes isolated from PBMCs, as previously described, at a 5:1 ratio in complete RPMI in the presence or absence of myelin peptides or viral antigens for 4 hours to assess responses of the CSF-derived T-cell lines to self-MHC or antigenic peptides. Brefeldin A (10 mg/mL) was added for an additional 14 hours of incubation, and thereafter, cells were analyzed for intracellular expression of IL-17, IFN-g, GM-CSF, and CD40L. In some experiments neutralizing anti-HLA-DR/DP/DQ antibodies (anti-MHC class II, 10 mg/ mL, clone Tu39, BD Biosciences) were added together with peptides.
ELISA
Cell-free supernatants of CSF, stored immediately after collection from patients with MS and those without MS, were analyzed by means of ELISA for CXCL10 (interferon-inducible protein 10, BioLegend), CCL5 (RANTES, BioLegend), CCL20 (R&D Systems), and CCL21 (secondary lymphoidtissue chemokine, eBioscience), according to the manufacturer's guidelines. 
RESULTS
CCR5
2 T H 1/T H 17 cells are a unique T CM subset that produces high levels of proinflammatory cytokines Relapses in patients with RR-MS are efficiently reduced by fingolimod, which sequesters T CM cells in lymph nodes, 39 suggesting that T CM cells can play a pathogenic role in patients with MS. Moreover, CD4
1 T cells producing GM-CSF, IFN-g, and IL-17 have a high pathogenic potential in mice with EAE and are recruited to the CNS of patients with MS. However, T CM cells are known to produce only low levels of effector cytokines, and therefore we first tried to identify human blood T CM cells that could coproduce these proinflammatory cytokines. To this aim, we used a combination of surface markers that directly correlate with expression of effector cytokines 40 and are involved in CNS homing. 41, 42 Thus, within the T-helper memory compartment ; Fig 1, A) . 40 In addition, we used CCR5 to discriminate T CM and T EM cells among T H 1 and T H 1/T H 17 subsets (Fig 1, A) . Indeed, CCR5
we used CXCR3 to identify IFN-g-producing cells (T H 1 cells), CCR6 to identify IL-17-producing cells (T H 17 cells), and coexpression of CXCR3 and CCR6 to identify IFN-g/IL-17-coproducing cells (T H 1/T H 17 cells
1 memory T cells lacked the T CM marker CCR7, whereas CCR5 2 memory T cells expressed high levels of CCR7 (Fig 1, B) , as expected. 17, 18 Based on this strategy, we purified and characterized 5 major subsets from the blood of HDs: T H 1 CM 
2 ) produced only low amount of effector cytokines (Fig 1, C) . Importantly, both T H 1/T H 17 CM and T H 1/T H 17 EM subsets contained a significant fraction of IFN-g/IL-17-coproducing cells and secreted high amounts of GM-CSF and IL-22 (Fig 1, C) . Furthermore, they expressed both RORC and T-bet (see Fig E1, A, in this article's Online Repository at www.jacionline.org), a functional IL-23R (see Fig E1, B) , and produced only low levels of the antiinflammatory cytokine IL-10 (see Fig E1, C) , indicating that they had a high pathogenic potential. Notably, although T H 1/T H 17 EM cells produced higher levels of IFN-g than T H 1/ T H 17 CM cells, production of IL-17, IL-22, and GM-CSF was comparable in the 2 T H 1/T H 17 subsets (Fig 1, C) . Also, conventional T H 17 cells produced IL-17, GM-CSF, and IL-22 and expressed RORC (Fig 1, C, and see Fig E1, A) . However, in contrast to T H 1/T H 17 cells, they expressed only low levels of Tbet (see Fig E1, A) and IFN-g but high levels of IL-10 (see Fig  1, C) , suggesting that they had only a limited pathogenic potential. 6 Finally, both T H 1 subsets expressed IFN-g, GM-CSF and T-bet, but T H 1 CM cells expressed only low levels. Moreover, expression of IL-17, IL-22, IL-23R, and RORC was hardly detectable in T H 1 cells (Fig 1, C, and see Fig E1, A and B) .
We conclude that CCR5 2 T H 1/T H 17 cells are a peculiar subset of T CM cells that produce high amounts of proinflammatory and potentially pathogenic effector cytokines.
T H 1/T H 17 CM cells are closely related to conventional T H 17 cells
Because T H 1/T H 17 cells express high levels of IFN-g, T-bet, and recognize antigens from intracellular pathogens 43 they appear to be a subset of T H 1 cells. To define the molecular relationships of T H 1/T H 17 subsets with T H 1 and T H 17 cells, we performed a genome-wide gene expression analysis (Fig 1, D , and see Table E2 in this article's Online Repository at www. jacionline.org). We identified 242 differentially expressed genes whose expression divided the analyzed populations into 2 major clusters, one containing all T H 1 populations and another containing T H 17 cells and both T H 1/T H 17 subsets (Fig 1, D) . Notably, in the T H 1 cluster T H 1 CM and T H 1 EM cells formed 2 distinct subclusters. Conversely, in the T H 17 cluster only T H 1/T H 17 EM cells formed a distinct subcluster, whereas T H 17 and T H 1/T H 17 CM cells clustered partially together. Among differentially expressed genes, IFNGR2 and the transcription factor FOXP1 44 were upregulated in T H 1 subsets. Conversely, T H 17 and T H 1/T H 17 subsets expressed higher levels of CD161, HLA-G, Blys, and STAT5B. Furthermore, both T EM subsets expressed higher levels of the MS-associated gene CD58, 45 and genes involved in cytotoxicity, such as eomesodermin, NKG7, and granzymes. Differential expression of CD161, Granzyme-A, and CD58 was confirmed at the protein level (see Fig E1, D) . IL-12 was inhibitory (Fig 1, E, left panels) . Reciprocally, T H 17 cells expressed high levels of CXCR3 under T H 1 conditions, whereas T H 17 conditions were detrimental (Fig 1, E, (Fig 1, E) .
In conclusion, the analysis of gene expression and cellular plasticity suggests that T H 1/T H 17 CM cells are closely related to T H 17 cells and more distantly to T H 1 cells.
Selective and systemic expansion of T H 1/T H 17 CM cells in patients with RR-MS
We then compared the ex vivo cytokine-producing capacities of total CD4
1 T cells in peripheral blood of patients with RR-MS with those of age-and sex-matched HDs and patients with progressive MS (Fig 2, A) . Among patients with RR-MS, we further discriminated between those with mild/stable disease (MSSS < 1) and those with more advanced/severe disease (MSSS > 1, see Table E1 ); the latter are of high clinical relevance because they frequently develop the progressive form, which is difficult to treat. CD4 1 T cells from peripheral blood of patients with RR-MS with severe disease (RR > 1) produced significantly higher amounts of IFN-g, IL-17, GM-CSF, and IL-22 compared with healthy subjects (Fig 2, A) . Importantly, the enhanced production of IFN-g, IL-17, and GM-CSF was not observed in patients with progressive MS or patients with RR-MS with mild disease (RR < 1). Conversely, IL-22 production was not significantly different in the analyzed cohorts of MS patients.
We then monitored the frequencies of relevant helper T-cell subsets in the blood of different cohorts of patients with MS to identify the cells responsible for the enhanced cytokine production. Strikingly, patients with RR-MS with severe but not those with progressive or mild disease had significantly higher frequencies of T H 1/T H 17 CM cells compared with healthy subjects (Fig 2, B) . Conversely, T H 17 cells were largely unaffected, and T H 1 subsets were even reduced. Notably, T H 1/T H 17 EM cells were not increased, in contrast to T H 1/T H 17 CM cells, but were selectively reduced in patients with RR-MS with mild disease.
In summary, patients with RR-MS with severe disease have systemic and selective expansion of T H 1/T H 17 CM cells, and CD4
1 T-cells in these patients with MS show consequently enhanced production of IFN-g, IL-17, and GM-CSF.
T H 1/T H 17 CM and T H 1 CM cells in patients with RR-MS respond selectively to self-antigens and viral antigens
We previously showed that total CCR6 1 T cells, which contain both T H 17 and T H 1/T H 17 subsets, are autoreactive in healthy individual subjects, 34 and therefore we asked whether the increased frequencies of T H 1/T H 17 CM cells in patients with RR-MS might be associated with autoreactive T-cell expansion. Thus we analyzed the proliferation of purified T-cell subsets in response to self-MHC displayed on ex vivo-isolated autologous CD1c 1 DCs in the absence of exogenous antigens. 34 In healthy subjects T H 17 cells showed the highest autoreactivity, and T H 1 CM cells showed the lowest autoreactivity (Fig 3, A, and see Fig E2, A, in this article's Online Repository at www.jacionline.org). Of note, T H 1/T H 17 subsets were poorly autoreactive in healthy subjects. This weak proliferation observed with autologous DCs reflected low autoreactivity but not reduced proliferative capacities because all T-cell subsets proliferated vigorously with allogeneic DCs (see Fig E2, A) . Strikingly, in patients with RR-MS, T H 1/T H 17 CM cells were highly autoreactive, whereas T H 1/T H 17 EM cells showed hardly any autoreactivity (Fig 3, A) . Also, T H 1 CM cells were poorly autoreactive in patients with RR-MS, whereas T H 17 cells showed some autoreactivity but were less autoreactive in patients with RR-MS than in healthy subjects (Fig 3, A) .
To understand whether T H 1/T H 17 CM cells reacted with selfantigens that are implicated in MS, we analyzed their proliferation with autologous monocytes loaded with myelin antigens (ie, MBP and myelin oligodendrocyte glycoprotein [MOG]-derived peptides). Notably, monocytes are much less potent antigen-presenting cells than DCs 49 and therefore are inefficient to induce T-cell proliferation in the absence of exogenous antigens and allow the assessment of antigen-specific responses, 34 including those to myelin self-antigens in patients with MS (see Fig E2, B) . In HDs we detected weak proliferation with MOG/ MBP peptides of T H 17 and T H 1 CM cells, whereas T H 1/T H 17 CM cells did not respond (Fig 3, B) . In marked contrast, in patients with RR-MS, myelin antigens consistently induced proliferation of T H 1/T H 17 CM cells (Fig 3, B , and see Fig E2, B) , whereas responses of T H 17 and T H 1 CM cells were low and undetectable, respectively.
We also assessed antigen specificities for EBV and JCV because these viruses are risk factors for MS development and therapy, respectively. In healthy subjects both T H 1/T H 17 CM and T H 1 CM cells proliferated vigorously with JCV-derived peptides (Fig 3, B) . In marked contrast, in patients with RR-MS, only T H 1 CM cells proliferated with JCV (Fig 3, B , and see Fig E2,  B) , whereas T H 1/T H 17 CM cells did not respond. T H 1 CM cells proliferated also with EBV-derived peptides, whereas T H 1/ T H 17 CM and T H 17 cells responded poorly or not at all.
In conclusion, T H 1/T H 17 CM cells are poorly autoreactive in healthy subjects and respond vigorously to JCV. In marked contrast, in patients with RR-MS, they become autoreactive but do not respond to JCV and switch thus from a protective to a potentially pathogenic response. Conversely, T H 1 CM cells are in all cases poorly autoreactive and contain virus-specific cells, suggesting that unlike T H 1/T H 17 CM cells, they maintain a protective antiviral function in patients with MS.
Myelin-reactive T H 1/T H 17 cells and virus-specific T H 1 cells are enriched in the CSF of patients with active MS
To characterize T cells that could home to the CNS, the site where disease develops, we analyzed CSF-infiltrating T cells, which have very similar characteristics as T cells in the leptomeninges. 50 The CSF of patients with MS collected briefly after an attack for diagnostic purposes contained significantly higher levels of the CXCR3 ligand CXCL10 compared with control subjects and also contained some CCL21, whereas CCL5 and CCL20 were hardly detectable (Fig 4, A) . Consistent with this chemokine pattern, CXCR3-expressing subsets (ie, T H 1/T H 17 and T H 1 cells) were highly abundant in the CSF of patients with MS (Fig 4, B) . Conversely, conventional T H 17 cells, which lack CXCR3 expression, were rare. Moreover, a majority of T H 1 and T H 1/T H 17 cells were CCR5 2 , suggesting that they were mainly derived from T CM cells (Fig 4, B) .
The total number of T cells that can be obtained from the CSF is very low, making a direct ex vivo analysis impossible. To overcome this limitation, we polyclonally expanded FACS-purified total T H 1, T H 1/T H 17, and T H 17 cell subsets and generated stable T-cell lines. Analysis of the TCR-Vb repertoire excluded monoclonal expansions (see Fig E3, A, in this article's Online Repository at www.jacionline.org). Moreover, all CSF-derived T-cell lines expressed high levels of CD40L, IFN-g, and GM-CSF on brief polyclonal stimulation, whereas IL-17 was produced mainly by T H 17 and T H 1/T H 17 cell lines (see Fig E3, B) .
In accordance to what we found in peripheral blood, T H 1/ T H 17 cells in the CSF were highly autoreactive because they performed effector functions following contact with autologous monocytes in the absence of exogenous antigens in patients with MS (Fig 4, C) . Thus they upregulated CD40L, which is induced on helper T cells on strong TCR stimulation, 34, 51 and produced IFN-g (Fig 4, C, and see Fig E3, C) . Conversely, T H 1 cells were poorly autoreactive in all patients, whereas T H 17 cells were autoreactive in only a single patient. Furthermore, myelin-derived peptides upregulated IFN-g, IL-17, and GM-CSF production selectively in T H 1/T H 17 cells, whereas T H 1 cells did not respond (Fig 4, D, and see Fig E3, C) . In contrast, JCV and, to a lesser extent, EBV induced IFN-g and GM-CSF production selectively in T H 1 cells but not in T H 1/T H 17 cells. Responses of T H 17 cells to all these antigens were undetectable. Neutralizing anti-MHC class II antibodies blocked cytokine production and CD40L upregulation by peptide-stimulated T H 1 and T H 1/T H 17 cells, confirming that these effector functions were TCR dependent (see Fig E3, C) . These data show that T H 1 cells and T H 1/T H 17 cells are enriched in the CSF of patients with MS shortly after an attack and that, as observed in peripheral blood, CSF-infiltrating T H 1 cells are specific for viral antigens, whereas CSF-infiltrating T H 1/T H 17 cells are autoreactive and react with myelin antigens. Furthermore, CSF-infiltrating T cells contain T CM -like cells and might be recruited through the CXCL10/CXCR3 axis.
52,53
Efficient but unselective targeting of T H 1/T H 17 CM cells by therapies that block lymphocyte migration from lymph nodes to the CNS Fingolimod and natalizumab efficiently reduce relapses in patients with RR-MS by blocking T-cell exit from lymph nodes and extravasation to the CNS, respectively.
15,16,19 These . Shown are box plots of divided cells after 7 days induced by specific peptides and statistical significances (analysis as in Fig 3, A) . *P < .05, **P < .005, and ***P < .0005.
treatments have not been approved for patients with progressive MS and have severe side effects. Nevertheless, parameters that predict the patient's responsiveness are missing. To address the effects of these therapies on T H 1/T H 17 CM cells, we analyzed the effects of natalizumab or fingolimod on the frequencies of different helper T-cell subsets in peripheral blood of treated and untreated patients with RR-MS. In natalizumab-treated patients the percentage of circulating CD4
1 T cells was comparable with those in untreated patients ( Fig 5, A) ; among these, the T H 1/T H 17 CM subset was enriched, and the T H 1 CM subset was reduced (Fig 5, B) . The latter was an unexpected finding because T H 1/T H 17 and T H 1 subsets expressed high and comparable levels of the a4/b1-integrin (Fig 5, C) . Interestingly, a relevant fraction of T H 1/T H 17 but also T H 1 and T H 17 cells in both peripheral blood and CSF coexpressed CCR7 and a4-integrin (see Fig E4, A, in this article's Online Repository at www.jacionline.org), suggesting that these peculiar cells could shuttle between lymph nodes and the CNS and were therefore susceptible to both natalizumab and fingolimod therapies. Consistently, we could detect T H 1/T H 17 CM , T H 1 CM , and T H 17 cells in human secondary lymphoid organs, and a relevant fraction of them expressed the a4/b1-integrin (data not shown).
In fingolimod-treated patients the majority of CD4 1 T cells were depleted from peripheral blood, as expected (Fig 5, A) . To quantify the treatment efficacy on different T-cell subsets, we calculated the fold decrease of T-cell subsets in treated versus untreated patients with RR-MS. Numbers of T H 1/T H 17 CM cells, but also T H 1 CM and T H 17 cells, were strongly reduced in peripheral blood of fingolimod-treated patients with MS (Fig 5, D) , whereas T H 1 EM and T H 1/T H 17 EM cells were less affected, as expected. 16 In summary, circulating T H 1/T H 17 CM cells coexpress CCR7 and the a4/b1-integrin and therefore could be targeted by both fingolimod and natalizumab, suggesting that the high efficacies of these treatments could rely on their common effects on potentially pathogenic autoreactive T H 1/T H 17 CM cells. Nevertheless, these treatments are not selective and also target virus-specific T H 1 cells that could perform immune surveillance and play a protective role.
DISCUSSION
MS is a disabling autoimmune disorder driven by autoreactive T cells. We provide strong evidence here that T H 1/T H 17 CM cells play a key pathogenic role in MS, whereas T H 1 cells are likely to be critical for antiviral immune surveillance of the CNS. 20 These findings advance significantly the understanding of MS pathogenesis and have important clinical implications. Critical properties that confer a high pathogenic potential to CD4 1 T cells have been identified in animal models of MS, but the phenotype of pathogenic precursor T cells in the blood of patients with RR-MS remained to be defined. Our data indicate a prominent pathogenic role for T H 1/T H 17 CM cells in relapses. This peculiar T-cell subset could migrate from lymph nodes to the CNS, produced pathogenic and MS-associated proinflammatory cytokines, was targeted by therapies that prevent relapses, and proliferated with myelin antigens selectively in patients with MS, strongly suggesting that it contained circulating precursors of pathogenic T cells. T H 1/T H 17 cells in the CSF of patients with MS were activated by nonprofessional antigen-presenting cells in the absence of exogenous antigens, suggesting that they were highly autoreactive, possibly because they express a degenerate TCR 54 Indeed, T H 1/T H 17 cells in healthy subjects recognize not only JCV but also influenza virus 8 and are required to control Mycobacterium tuberculosis infections. 56 Neurotropic viruses are critical risk factors for the development 27, 29 and therapy 22, 23 of MS, but they are not present in standard animal MS models, such as EAE, and how they promote MS is poorly understood. 29 We found that patients with MS had a reduced CD4
1 T-cell response to JCV. In HDs both T H 1 and T H 1/T H 17 cells reacted strongly with JCV. In contrast, patients with MS lacked JCV-specific T H 1/T H 17 cells and had overall reduced frequencies of T H 1 cells. The paucity of conventional T H 1 cells and lack of polyfunctional, JCV-specific T H 1/ T H 17 cells in patients with MS might explain their susceptibility to JCV reactivations after natalizumab treatment. 22, 23 Exaggerated antiviral T-cell responses and JCV itself can induce CNS damage, 27, 29 but the physiologic control of JCV, EBV, and other persistent neurotropic viruses in healthy subjects does not cause immunopathology. Moreover, the activity of virus-specific T cells is limited in time and space by the presentation of viral antigens. These findings suggest that T H 1 cells in patients with MS are critical to contain JCV but are insufficient to induce relapses in the absence of autoreactive T H 1/T H 17 cells.
Natalizumab is one of the most efficient therapies to prevent relapses. It does not deplete pathogenic lymphocytes but blocks their homing to the CNS. 19 Consequently, it leads to the accumulation of activated proinflammatory T cells in the circulation of treated patients with MS. 57 Consistently, numbers of potentially pathogenic T H 1/T H 17 CM cells were selectively increased in peripheral blood of natalizumab-treated patients, whereas on the contrary, numbers of conventional T H 1 cells were further reduced. The imbalance between T H 1 and T H 1/T H 17 cells in patients with MS suggests that T H 1 and T H 1/T H 17 subsets compete for the same homeostatic niche. [58] [59] [60] Indeed, among CD4 1 T cells, only T H 1 and T H 1/T H 17 cells express high levels of T-bet, which induces an IL-15-dependent lifestile. 18, 58, 61 Natalizumab further reduces the ratio of T H 1 to T H 1/T H 17 cells, presumably by favoring interactions of autoreactive T H 1/T H 17 CM cells in lymph nodes with DCs, which present self-MHC but could also transpresent IL-15. 49, 62 In addition, natalizumab might limit the access of antiviral T H 1 cells to IL-15-rich tissues. 58, 59 Viruses were proposed to promote MS through molecular mimicry. 30, 32 Our results support an alternative but not mutually exclusive 63 scenario that could explain the permissive role of viruses in patients with MS (see Fig E5 in this article' s Online Repository at www.jacionline.org). Healthy subjects are persistently infected with many different viruses, and several of these viruses latently infect the CNS. The reactivation of latent viruses in the CNS leads to type 1 Interferon and CXCL10 production. Virusspecific T H 1 and T H 1/T H 17 cells could then be recruited in a CXCR3-dependent manner to the CNS to control the virus. In patients with MS, this physiologic immune surveillance appears to be disturbed because viral reactivations lead not only to the recruitment of virus-specific T H 1 cells but also that of autoreactive T H 1/T H 17 bystander cells. Although virusactivated T H 1 cells might be important to induce early inflammation, T H 1/T H 17 cells could perpetuate the response after viral control and extend it to uninfected areas where they could even induce de novo viral reactivations. 21 Indeed, latent and lytic EBV is present in brain lesions of patients with MS. 64, 65 In addition, T H 1/T H 17 cells produce IL-17 that is directly neurotoxic 66 and could enhance permeability of the blood-brain barrier. 67 Thus in this scenario reactivations of JCV, EBV, or any other persistent neurotropic virus could promote relapses by recruiting autoreactive T H 1/T H 17 cells to the CNS, providing a plausible explanation for the enigmatic associations of MS with several different neurotropic viruses (see Fig E5) . 28, 29 Finally, our findings have several relevant implications for prognosis and therapy of MS. First, the presence of autoreactive T H 1/T H 17 cells in the CSF is a candidate prognostic marker for clinically isolated syndromes that progress to MS. Second, the systemic expansion of autoreactive T H 1/T H 17 CM cells is expected to predict the risk of future relapse in patients with RR-MS. Third, the tissue-homing potentials of autoreactive T H 1/T H 17 cells could predict preferential responsiveness to fingolimod or natalizumab. Fourth, therapies that selectively target T H 1/T H 17 cells but spare T H 1 cells could be highly efficient without causing JCV reactivations and PML. Indeed, in contrast to T H 1 cells, T H 1/T H 17 cells express high levels of CCR6, CD161, and IL-17, which could be targeted in future therapies. 41, 66, 68 Clinical implications: T H 1/T H 17 CM cells are a candidate prognostic marker for MS, and future therapies that selectively target these autoreactive T cells might prevent relapses without the risk of PML.
